USP22-depleted tumor cells exhibited a high sensitivity to HSP90 inhibitor ganetespib, suggesting that targeting USP22 and HSP90β may prove effective for the treatment of breast and colorectal cancer (55). Here, HSP90AB1 is linked to colorectal cancer.